Form 4: BioLargo Director Dennis E. Marshall Receives Option Grants
SEC Form 4
Director Dennis E. Marshall receives option grants to purchase common stock as compensation for services and replacement of expired options.
Summary
- Dennis E. Marshall, a director of BioLargo, Inc., was granted options to purchase common stock.
- On September 29, 2024, Marshall received an option to purchase 93,749 shares at an exercise price of $0.24, replacing a previously expired option.
- On September 30, 2024, Marshall received an option to purchase 81,522 shares at an exercise price of $0.23 as payment for $18,750 in board service fees.
- Following these transactions, Marshall directly owns options to purchase 4,471,805 shares of BioLargo common stock.
Sentiment
Score: 6
Explanation: The sentiment is neutral as it reports routine compensation practices. The option grants are a standard way to incentivize directors.
Positives
- The option grants align director compensation with company performance.
- The replacement of the expired option ensures continued incentive for the director.
Future Outlook
NA
Industry Context
Option grants to directors are a common practice in publicly traded companies to align their interests with those of shareholders and incentivize performance.
Comparison to Industry Standards
- Option grants are a standard form of compensation for directors in publicly traded companies, particularly in smaller companies like BioLargo.
- The size of the grants and the exercise prices would need to be compared to similar companies in the environmental technology sector to determine if they are in line with industry norms.
- Companies like Xylem, Inc. and Danaher Corporation, while much larger, also utilize equity-based compensation for their directors.
Related Party Transactions
- The option grant to Dennis E. Marshall is a related party transaction as he is a director of BioLargo, Inc.
Stakeholder Impact
- The option grants could potentially dilute existing shareholders if the options are exercised.
- The grants incentivize the director to work towards increasing shareholder value.
Key Dates
| Date | Description |
|---|---|
| February 14, 2017 | Date of Limited Power of Attorney for Section 16 Reporting Obligations. |
| September 29, 2024 | Date of option grant for 93,749 shares at $0.24. |
| September 29, 2034 | Expiration date of option grant for 93,749 shares at $0.24. |
| September 30, 2024 | Date of option grant for 81,522 shares at $0.23. |
| September 30, 2034 | Expiration date of option grant for 81,522 shares at $0.23. |
| October 01, 2024 | Date of signature by attorney-in-fact. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.